PG
UTHR icon

Pendal Group’s United Therapeutics UTHR Stock Holding History

Pendal Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-37,728
Closed -$4.43M – 475
2019
Q1 		$4.43M Sell
37,728
-4,068
-10% -$474K 0.06% 149
2018
Q4 		$4.55M Sell
41,796
-3,101
-7% -$360K 0.07% 138
2018
Q3 		$5.74M Sell
44,897
-3,272
-7% -$405K 0.08% 131
2018
Q2 		$5.45M Hold
48,169
– – 0.07% 153
2018
Q1 		$5.41M Sell
48,169
-8,097
-14% -$1.03M 0.07% 163
2017
Q4 		$8.32M Sell
56,266
-4,137
-7% -$526K 0.11% 134
2017
Q3 		$7.16M Sell
60,403
-9,564
-14% -$1.22M 0.09% 147
2017
Q2 		$9.08M Buy
+69,967
New +$8.73M 0.13% 120

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pendal Group's UTHR Position: Q2 2019 in Review

Pendal Group sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 37,728 shares — an estimated $4.43M sold.

Pendal Group first reported a position in UTHR in Q2 2017 and held it in 8 quarters. The position peaked at $9.08M in Q2 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

  • Pendal Group reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pendal Group sold 37,728 United Therapeutics shares in Q2 2019, an estimated $4.43M.
  • Pendal Group first reported a position in United Therapeutics in Q2 2017 and held it in 8 quarters.
  • Pendal Group's United Therapeutics position peaked at $9.08M in Q2 2017.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Pendal Group's 13F filing for Q2 2019, filed 1 Aug 2019.